Noesis Capital Mangement Corp reduced its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 5.7% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,178 shares of the company’s stock after selling 434 shares during the period. Noesis Capital Mangement Corp’s holdings in Johnson & Johnson were worth $1,113,000 at the end of the most recent reporting period.
A number of other large investors have also recently made changes to their positions in JNJ. Camden National Bank raised its stake in Johnson & Johnson by 1.3% during the 1st quarter. Camden National Bank now owns 59,459 shares of the company’s stock valued at $9,216,000 after purchasing an additional 762 shares during the period. Guardian Investment Management raised its stake in Johnson & Johnson by 6.6% during the 1st quarter. Guardian Investment Management now owns 28,734 shares of the company’s stock valued at $4,722,000 after purchasing an additional 1,774 shares during the period. Alliance Wealth Management Group raised its stake in Johnson & Johnson by 2.4% during the 1st quarter. Alliance Wealth Management Group now owns 5,916 shares of the company’s stock valued at $917,000 after purchasing an additional 140 shares during the period. ProVise Management Group LLC raised its stake in Johnson & Johnson by 2.6% during the 1st quarter. ProVise Management Group LLC now owns 38,133 shares of the company’s stock valued at $5,911,000 after purchasing an additional 968 shares during the period. Finally, Lindenwold Advisors INC raised its stake in Johnson & Johnson by 1.4% during the 1st quarter. Lindenwold Advisors INC now owns 8,357 shares of the company’s stock valued at $1,295,000 after purchasing an additional 118 shares during the period. 67.57% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
JNJ has been the topic of several recent analyst reports. JPMorgan Chase & Co. lifted their target price on Johnson & Johnson from $175.00 to $180.00 and gave the company a “neutral” rating in a research note on Friday, July 21st. Raymond James lifted their price objective on Johnson & Johnson from $181.00 to $184.00 and gave the stock an “outperform” rating in a research note on Monday, July 24th. TheStreet downgraded Johnson & Johnson from a “b” rating to a “c+” rating in a research note on Friday, May 19th. Atlantic Securities lifted their price objective on Johnson & Johnson from $167.00 to $170.00 and gave the stock a “neutral” rating in a research note on Friday, August 4th. Finally, Credit Suisse Group lifted their price objective on Johnson & Johnson from $170.00 to $175.00 and gave the stock a “neutral” rating in a research note on Friday, July 21st. Eight research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $171.80.
Johnson & Johnson Stock Performance
NYSE JNJ opened at $173.85 on Monday. The business’s 50 day moving average price is $164.90 and its 200-day moving average price is $161.14. Johnson & Johnson has a fifty-two week low of $150.11 and a fifty-two week high of $181.04. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.88 and a current ratio of 1.12. The company has a market cap of $451.83 billion, a P/E ratio of 35.19, a P/E/G ratio of 2.92 and a beta of 0.54.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its quarterly earnings data on Thursday, July 20th. The company reported $2.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.62 by $0.18. Johnson & Johnson had a return on equity of 36.72% and a net margin of 13.35%. The company had revenue of $25.53 billion during the quarter, compared to analysts’ expectations of $24.63 billion. During the same quarter in the previous year, the business earned $2.59 EPS. Johnson & Johnson’s revenue was up 6.3% compared to the same quarter last year. Sell-side analysts predict that Johnson & Johnson will post 10.75 earnings per share for the current year.
Johnson & Johnson Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 7th. Investors of record on Monday, August 28th will be issued a dividend of $1.19 per share. This represents a $4.76 dividend on an annualized basis and a yield of 2.74%. The ex-dividend date is Friday, August 25th. Johnson & Johnson’s payout ratio is currently 96.36%.
Insider Activity at Johnson & Johnson
In other Johnson & Johnson news, VP Peter Fasolo sold 20,000 shares of the company’s stock in a transaction on Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total value of $3,406,400.00. Following the completion of the sale, the vice president now directly owns 102,696 shares in the company, valued at approximately $17,491,182.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other Johnson & Johnson news, VP Peter Fasolo sold 20,000 shares of the company’s stock in a transaction on Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total value of $3,406,400.00. Following the completion of the sale, the vice president now directly owns 102,696 shares in the company, valued at approximately $17,491,182.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider William Hait sold 14,698 shares of the company’s stock in a transaction on Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total value of $2,528,056.00. Following the completion of the sale, the insider now owns 87,747 shares of the company’s stock, valued at $15,092,484. The disclosure for this sale can be found here. Insiders sold a total of 47,163 shares of company stock worth $7,928,856 in the last quarter. 0.20% of the stock is owned by company insiders.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Stories
- Five stocks we like better than Johnson & Johnson
- Are Penny Stocks a Good Fit for Your Portfolio?
- MarketBeat Week in Review – 8/7 – 8/11
- What Are Dividend Champions? How to Invest in the Champions
- 3 Retailers To Watch Closely Next Week
- How to Use Stock Screeners to Find Stocks
- Investing in Coffee: 3 Great Strategies to Consider
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
